Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

Prostate Cancer

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 32 articles: HTML format

Single Articles

October 2023
1. APARICIO A
   Biochemical Recurrence in Prostate Cancer - Tilting the Scale.
   N Engl J Med. 2023;389:1522-1523.
   PubMed    
   
   
   
2. FREEDLAND SJ, de Almeida Luz M, De Giorgi U, Gleave M, et al
   Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
   N Engl J Med. 2023;389:1453-1465.
   PubMed     Abstract available
   
   
   
3. NADAMUNI M, D'Amico AV, Donovan JL, Hamdy FC, et al
   Decision Making in Prostate Cancer.
   N Engl J Med. 2023;389:1335-1338.
   PubMed    
   
   
   July 2023
4. PINSKY PF, Parnes H
   Screening for Prostate Cancer. Reply.
   N Engl J Med. 2023;389:94.
   PubMed    
   
   
   
5. PRESTI J JR, Alexeeff S, Avins AL
   Screening for Prostate Cancer.
   N Engl J Med. 2023;389:93-94.
   PubMed    
   
   
   
6. INAMURA K
   Screening for Prostate Cancer.
   N Engl J Med. 2023;389:93.
   PubMed    
   
   
   
7. HOOVER J, Butterfass C, Ponder A
   Screening for Prostate Cancer.
   N Engl J Med. 2023;389:92-93.
   PubMed    
   
   
   
8. HAMDY FC, Donovan JL
   Fifteen-Year Outcomes of the ProtecT Trial for Localized Prostate Cancer. Reply.
   N Engl J Med. 2023;389:92.
   PubMed    
   
   
   
9. DAVIS MJ, Stephens A, Abdollah F
   Fifteen-Year Outcomes of the ProtecT Trial for Localized Prostate Cancer.
   N Engl J Med. 2023;389:90-92.
   PubMed    
   
   
   June 2023
10. 
    Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
    N Engl J Med. 2023;388:2208.
    PubMed    
    
    
    April 2023
11. 
    Waiting on Prostate Cancer.
    N Engl J Med. 2023;388:e54.
    PubMed    
    
    
    
12. PINSKY PF, Parnes H
    Screening for Prostate Cancer.
    N Engl J Med. 2023;388:1405-1414.
    PubMed    
    
    
    March 2023
13. SARTOR O
    Localized Prostate Cancer - Then and Now.
    N Engl J Med. 2023 Mar 11. doi: 10.1056/NEJMe2300807.
    PubMed    
    
    
    
14. HAMDY FC, Donovan JL, Lane JA, Metcalfe C, et al
    Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
    N Engl J Med. 2023 Mar 11. doi: 10.1056/NEJMoa2214122.
    PubMed     Abstract available
    
    
    February 2023
15. FIZAZI K, Piulats JM, Reaume MN, Ostler P, et al
    Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
    N Engl J Med. 2023 Feb 16. doi: 10.1056/NEJMoa2214676.
    PubMed     Abstract available
    
    
    
16. GAGLIANO-JUCA T, Hirsch MS, McGregor BA, Basaria S, et al
    Failure of Androgen-Deprivation Therapy Due to Ectopic hCG Secretion.
    N Engl J Med. 2023;388:660-662.
    PubMed    
    
    
    December 2022
17. GULATI R
    Reducing Prostate Cancer Overdiagnosis.
    N Engl J Med. 2022;387:2187-2188.
    PubMed    
    
    
    
18. HUGOSSON J, Mansson M, Wallstrom J, Axcrona U, et al
    Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only.
    N Engl J Med. 2022;387:2126-2137.
    PubMed     Abstract available
    
    
    September 2022
19. 
    Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
    N Engl J Med. 2022;387:860.
    PubMed    
    
    
    June 2022
20. SMITH MR
    Darolutamide in Metastatic Prostate Cancer. Reply.
    N Engl J Med. 2022;386:2345.
    PubMed    
    
    
    
21. BOWLING GC, Dimitrakoff JD
    Darolutamide in Metastatic Prostate Cancer.
    N Engl J Med. 2022;386:2344.
    PubMed    
    
    
    
22. TURCO F, Tucci M, Buttigliero C
    Darolutamide in Metastatic Prostate Cancer.
    N Engl J Med. 2022;386:2344.
    PubMed    
    
    
    February 2022
23. SMITH MR, Hussain M, Saad F, Fizazi K, et al
    Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
    N Engl J Med. 2022 Feb 17. doi: 10.1056/NEJMoa2119115.
    PubMed     Abstract available
    
    
    December 2021
24. SARTOR O, Morris MJ, Kraus BJ
    Lutetium-177-PSMA-617 for Prostate Cancer. Reply.
    N Engl J Med. 2021;385:2495-2496.
    PubMed    
    
    
    
25. DALLA VOLTA A, Grisanti S, Berruti A
    Lutetium-177-PSMA-617 for Prostate Cancer.
    N Engl J Med. 2021;385:2495.
    PubMed    
    
    
    
26. KASHIHARA T, Kashihara K
    Lutetium-177-PSMA-617 for Prostate Cancer.
    N Engl J Med. 2021;385:2494-2495.
    PubMed    
    
    
    
27. HINDIE E
    Lutetium-177-PSMA-617 for Prostate Cancer.
    N Engl J Med. 2021;385:2494.
    PubMed    
    
    
    November 2021
28. EKLUND M, Discacciati A, Nordstrom T
    MRI-Targeted Biopsy in Prostate Cancer Screening. Reply.
    N Engl J Med. 2021;385:2110-2111.
    PubMed    
    
    
    
29. YOSHIDA S, Fujii Y
    MRI-Targeted Biopsy in Prostate Cancer Screening.
    N Engl J Med. 2021;385:2110.
    PubMed    
    
    
    
30. AL HUSSEIN AL AWAMLH B, Spratt DE, Shoag JE
    MRI-Targeted Biopsy in Prostate Cancer Screening.
    N Engl J Med. 2021;385:2109-2110.
    PubMed    
    
    
    July 2021
31. EKLUND M, Jaderling F, Discacciati A, Bergman M, et al
    MRI-Targeted or Standard Biopsy in Prostate Cancer Screening.
    N Engl J Med. 2021 Jul 9. doi: 10.1056/NEJMoa2100852.
    PubMed     Abstract available
    
    
    June 2021
32. SARTOR O, de Bono J, Chi KN, Fizazi K, et al
    Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
    N Engl J Med. 2021 Jun 23. doi: 10.1056/NEJMoa2107322.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.